Harvard Apparatus Regenerative Technology
147 articles about Harvard Apparatus Regenerative Technology
-
Biostage Closes $3.6 Million Private Placement at a price of $3.60 per share
5/31/2018
Biostage, Inc .(OTCQB: BSTG), today announced that the Securities Purchase Agreements with Chu Bogang and Zhou Heping previously disclosed on Form 8-K have been fully funded and closed.
-
Hong Yu Appointed President of Biostage
5/31/2018
Biostage, Inc. has elected Hong Yu as President, effective May 29, 2018.
-
Biostage Reports 2018 First Quarter Financial Results
5/10/2018
Steady progress in the new year signals strengthening financial and technology positions
-
Biostage to Host Conference Call to Discuss First Quarter 2018 Financial Results and Operations
5/4/2018
- Conference Call with Live Audio Webcast on Thursday, May 10th at 9:00 AM ET -
-
Biostage Reports 2017 Financial Results
4/2/2018
Fourth Quarter Headcount Reduction and Private Placement Extend Operational Runway.
-
Biostage awarded SBIR Fast-Track grant to develop Cellspan™ Esophageal Implant (CEI) as a novel treatment for esophageal atresia in pediatric patients
3/29/2018
Biostage, Inc. announced it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant by the Eunice Kennedy National Institute of Child Health and Human Development (NICHD).
-
Biostage Names Distinguished Children's Hospital Executive James Shmerling to its Board of Directors
3/29/2018
Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that it has appointed James Shmerling, DHA, FACHE, President and Chief Executive Officer of Connecticut Children's Medical Center to its Board of Directors.
-
Biostage Preclinical Study Results Published in New Report
3/13/2018
Large-animal study results published in Nature Scientific Reports show successful esophageal regeneration.
-
Biostage Closes $1 Million Private Placement
2/20/2018
-
Biostage Appoints to its Scientific Advisory Board Charles S. Cox, Jr., MD
2/12/2018
The Scientific Advisory Board's role is to provide scientific guidance and governance for Biostage's research and development programs.
-
Biostage Names Jason Chen Chairman of its Board of Directors
2/8/2018
Mr. Chen is a broadly skilled senior executive with over 20 years of leadership experience in global commerce and advancing foreign corporate interests in China.
-
Biostage Appoints to its Scientific Advisory Board Christine Finck, MD, Executive VP, Surgeon-in-Chief at Connecticut Children's Medical Center
1/31/2018
The Scientific Advisory Board's role is to provide scientific guidance and governance for Biostage's research and development programs.
-
Biostage Closes $4.2M Private Placement
1/3/2018
Connecticut Children's Medical Center also participated in the transaction, by purchasing additional securities.
-
Biostage Announces Binding Agreement for $4M Private Placement
12/15/2017
The investor advanced a $300,000 deposit on the private placement proceeds concurrently with the MOU's execution.
-
An investor decision to renege on acquiring more than $3 million worth of stock has created a financial catastrophe for Biostage.
-
Biostage To Move To OTCQB Marketplace
10/6/2017
-
Biostage Reports 2017 Second Quarter Financial Results
8/14/2017
-
Biostage To Host Conference Call To Discuss Second Quarter 2017 Financial Results And Business Update
8/4/2017
-
Biostage Granted Continued Listing On Nasdaq
7/10/2017
-
Biostage Announces Agreement To Conduct $3.1 Million Private Placement At Market
6/27/2017